Cardiol Therapeutics (CRDL) Competitors $1.01 -0.05 (-4.72%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDL vs. AURA, CYRX, RNAC, TSVT, AQST, TSHA, ATXS, ATYR, ATAI, and CMPSShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Aura Biosciences (AURA), Cryoport (CYRX), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Aquestive Therapeutics (AQST), Taysha Gene Therapies (TSHA), Astria Therapeutics (ATXS), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Aura Biosciences Cryoport Cartesian Therapeutics 2seventy bio Aquestive Therapeutics Taysha Gene Therapies Astria Therapeutics Atyr PHARMA Atai Life Sciences COMPASS Pathways Aura Biosciences (NASDAQ:AURA) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Do institutionals & insiders have more ownership in AURA or CRDL? 96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.4% of Aura Biosciences shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor AURA or CRDL? In the previous week, Cardiol Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 9 mentions for Cardiol Therapeutics and 8 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.15 beat Cardiol Therapeutics' score of 0.07 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiol Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, AURA or CRDL? Aura Biosciences is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$76.41M-$1.75-3.09Cardiol TherapeuticsN/AN/A-$20.84M-$0.37-2.73 Does the MarketBeat Community believe in AURA or CRDL? Cardiol Therapeutics received 3 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 67.44% of users gave Cardiol Therapeutics an outperform vote while only 61.90% of users gave Aura Biosciences an outperform vote. CompanyUnderperformOutperformAura BiosciencesOutperform Votes2661.90% Underperform Votes1638.10% Cardiol TherapeuticsOutperform Votes2967.44% Underperform Votes1432.56% Is AURA or CRDL more profitable? Aura Biosciences' return on equity of -41.57% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -41.57% -36.43% Cardiol Therapeutics N/A -194.40%-129.07% Which has more volatility and risk, AURA or CRDL? Aura Biosciences has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500. Do analysts recommend AURA or CRDL? Aura Biosciences currently has a consensus price target of $22.75, indicating a potential upside of 321.30%. Cardiol Therapeutics has a consensus price target of $8.40, indicating a potential upside of 731.68%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Aura Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 SummaryCardiol Therapeutics beats Aura Biosciences on 9 of the 15 factors compared between the two stocks. Remove Ads Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.44M$2.85B$5.28B$7.36BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-2.5930.3821.6317.68Price / SalesN/A433.44371.0892.88Price / CashN/A168.6838.1534.64Price / Book3.163.416.373.94Net Income-$20.84M-$72.06M$3.20B$247.45M7 Day Performance10.38%0.83%1.79%0.48%1 Month Performance-10.62%-18.82%-9.41%-7.08%1 Year Performance-41.28%-30.46%9.61%-0.35% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics1.821 of 5 stars$1.01-4.7%$8.40+731.7%-40.8%$83.44MN/A-2.5920Analyst ForecastNews CoverageGap UpAURAAura Biosciences1.9829 of 5 stars$5.52+1.7%$22.75+312.1%-26.2%$277.24MN/A-3.1950Short Interest ↑Gap DownCYRXCryoport2.6779 of 5 stars$5.49+2.8%$11.83+115.5%-67.0%$274.01M$228.39M-1.621,020Analyst ForecastGap DownRNACCartesian Therapeutics1.7275 of 5 stars$10.11+1.1%$42.14+316.8%-37.0%$261.92M$38.91M-0.1964Gap UpTSVT2seventy bio2.0587 of 5 stars$4.95flat$6.67+34.7%-0.3%$259.07M$37.86M-2.66440Short Interest ↓High Trading VolumeAQSTAquestive Therapeutics1.7607 of 5 stars$2.62-3.3%$10.57+303.5%-34.8%$259.04M$57.56M-5.82160Gap DownTSHATaysha Gene Therapies2.9789 of 5 stars$1.24+1.6%$6.63+434.3%-52.3%$254.20M$8.33M1.97180Gap DownATXSAstria Therapeutics2.4519 of 5 stars$4.50-3.4%$26.60+491.1%-62.4%$253.95MN/A-2.1530Positive NewsATYRAtyr PHARMA2.729 of 5 stars$2.85+8.8%$18.60+552.6%N/A$253.25M$235,000.00-3.0353Positive NewsATAIAtai Life Sciences2.9175 of 5 stars$1.27-3.1%$10.50+726.8%-32.9%$251.85M$308,000.00-1.5780Positive NewsCMPSCOMPASS Pathways2.5499 of 5 stars$2.70-0.4%$20.20+648.1%-63.7%$250.22MN/A-1.23120Positive News Remove Ads Related Companies and Tools Related Companies AURA Alternatives CYRX Alternatives RNAC Alternatives TSVT Alternatives AQST Alternatives TSHA Alternatives ATXS Alternatives ATYR Alternatives ATAI Alternatives CMPS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDL) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRDL Stock Free CRDL Stock Alerts